🔴 Haemonetics is trading 4.36% down today after lowering its full-year margin expansion outlook

Haemonetics is trading at $121.86, down 4.36%, after lowering its full-year adjusted operating-margin expansion outlook to 0–50 basis points from 50–100 basis points. - Quarterly revenue and earnings beat estimates; reporting cited investor concern over lower margin guidance and growth spending. - It raised full-year revenue growth guidance to 8–11% and organic growth to 6–9%, while highlighting CSL’s planned NexSys rollout across U.S. centers by year-end 2027. - Broader markets were sharply lower, adding pressure, though the reduced margin outlook is a company-specific concern.